This therapy aims to address severe behavioural problems and offending behaviour in adolescents who are at risk of Child Criminal Exploitation (CCE), gang involvement, County Lines involvement and other Extra-Familial Harm (EFH). Other
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: ONE OR MORE OF: Known to services due to concerns in the last 12 months around: 1. Child sexual exploitation (CSE) 2. Child criminal exploitation (CCE) 3. Missing (from home or care) episodes 4. Potential or actual gang or CLDN affiliation as identified by police or other statutory service 5. Repeated school exclusion or absence 6. Involvement as a perpetrator or victim of youth violence or criminality OR TWO OR MORE OF THE FOLLOWING (OVER THE LAST 12 MONTHS): 7. Family conflict or inadequate supervision 8. Associating with antisocial peers 9. Concerns about alcohol or drug use AND EITHER 10. Index child/young person is living at home 50% or more each week. OR 11. Index child/young person is currently in an out of home placement, but with a clear return home plan (discussed on a case-by-case basis). AND 12. Caregiver(s) and index child/young person are willing to engage in family therapy.
Exclusion criteria
Exclusion criteria: 1. Index child/young person is actively homicidal, suicidal, or psychotic. 2. Problem sexual behaviour is the central concern. 3. Presence of organic and/or cognitive conditions that may have prevented family members making use of talking therapy. 4. Key family members, defined as “major players” in FFT-G, refuse family-based therapy. 5. Significant child protection concerns: basic needs of children are not being met. 6. Family have plans to move out of borough, thereby making therapy unfeasible within five months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Offending is measured using the International Self-Report Delinquency Study 4 survey offending scale (ISRD4; Marshall et al., 2022), completed by YP at baseline, post-treatment (6 months after randomisation) and follow-up (12 months after randomisation). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. YP Mental Health and Adjustment measured using Strengths and Difficulties Questionnaire (Goodman, 2005) at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. YP and caregiver report. 2. Child Criminal Exploitation measured using SRD4 additional items at at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. YP report. 3. Substance Misuse measured using ISRD3 substance misuse subscale (Marshall et al., 2013) at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. YP report. 4. Parental Mental Health measured using DASS-21 (Henry & Crawford, 2005) at at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. Caregiver report. 5. Parenting Supervision, Knowledge, and YP Disclosure measured using ISRD3 (Marshall et al., 2013) at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. YP report. 6. Family Functioning measured using SCORE-15 (Fay et al., 2013) at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. YP and caregiver report. 7. Parental Self-Efficacy measured using BPSES (Woolgar et al., 2023) at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. Caregiver report. 8. Attachment Representation measured using AAQ (Bodfield et al., 2020) at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. YP report. 9. YP Self-Efficacy measured using NGSE (Chen et al., 2001) at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. YP report. 10. Callous-Unemotional (CU) Traits measured using CU Traits MAP (Hawes et al., 2020) at baseline and post-treatment (6 months) and follow-up (12 months) post randomisation. Caregiver report. 11. Temperamental Irritability measured using ODD subtyping DSM items (Stringaris & Goodman, 2009) at baseline and post-treatment (6 months) and follow-up (12 mon | — |
Countries
England, United Kingdom